Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

SYN-001Positive

AI Analysis

Summary

Synaptiq Therapeutics was launched to acquire the clinical-stage SYN-001 program from Nobias Therapeutics, an FDA-designated orphan and rare pediatric disease therapeutic candidate for 22q11.2 Deletion Syndrome. The company plans to advance the program with a Phase IIb trial.

Clinical Trial Data

Phase

Phase IIb

Outcome Details

Synaptiq Therapeutics formed and acquired clinical-stage SYN-001 program from Nobias Therapeutics

Importance:5/10

Sentiment:

0.50

acquisitionorphan_diseaserare_pediatric_diseaseclinical_stageneuropsychiatry

Read the original article

Published by PR Newswire Pharma on July 23, 2026 12:56 PM

Read Original